Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855491 | 0.85 | BCAT2 (0.64) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL11200675 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL2427167 | 0.83 | CNR1 (0.70) | CNR1MTNR1AMTNR1BEPHX2CNR2 | |
| SCHEMBL9482772 | 0.83 | RAB9A (0.45) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL5142002 | 0.82 | TACR1 (0.53) | SMN1; SMN2TACR1LMNASLC1A2SLC1A1 | |
| SCHEMBL5142006 | 0.82 | TACR1 (0.56) | SMN1; SMN2TACR1LMNASLC1A2SLC1A1 | |
| SCHEMBL15671577 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 | |
| SCHEMBL7310626 | 0.81 | MMP2 (0.60) | TACR1LMNASLC1A2SLC1A1CNR1 | |
| SCHEMBL6290368 | 0.81 | TACR1 (0.51) | SMN1; SMN2TACR1LMNASLC1A2SLC1A1 | |
| SCHEMBL5455431 | 0.80 | CNR1 (0.57) | ALDH1A1HTTNCOA1SMN1; SMN2NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| EP-0104604-B1 | 1,2,3,4-TETRAHYDRO-1-AMINOMETHYL-4-PHENYL ISOQUINOLINES AND METHODS OF PREPARATION | PENNWALT CORPORATION (US) | 1988-05-18 | — | — | EP | disclosed |
| EP-0107825-B1 | 1,3,4,6,7,11B-HEXAHYDRO-7-ARYL-2H-PYRAZINO (2,1-ALPHA) ISOQUINOLINES USEFUL AS INTERMEDIATES AND PHARMACEUTICAL COMPOUNDS AND METHODS OF PREPARATION | PENNWALT CORPORATION (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4518779-A | 1,2,3,4-Tetrahydro-1-aminomethyl-4-phenyl isoquinolines | PENNWALT CORPORATION (US) | 1985-05-21 | — | — | US | disclosed |
| US-4517187-A | 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants | PENNWALT CORPORATION (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0107825-A1 | 1,3,4,6,7,11b-Hexahydro-7-aryl-2H-pyrazino (2,1-alpha) isoquinolines useful as intermediates and pharmaceutical compounds and methods of preparation | PENNWALT CORPORATION (US) | 1984-05-09 | — | — | EP | disclosed |
| EP-0104604-A1 | 1,2,3,4-Tetrahydro-1-aminomethyl-4-phenyl isoquinolines and methods of preparation | PENNWALT CORPORATION (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885HTT 2557/4885NCOA1 725/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | ALDH1A1 489/4885HTT 1961/4885NCOA1 956/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 281/4885HTT 2259/4885NCOA1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.